NO20050445L - Synergistisk interaksjon mellom abacavir og alovudin - Google Patents
Synergistisk interaksjon mellom abacavir og alovudinInfo
- Publication number
- NO20050445L NO20050445L NO20050445A NO20050445A NO20050445L NO 20050445 L NO20050445 L NO 20050445L NO 20050445 A NO20050445 A NO 20050445A NO 20050445 A NO20050445 A NO 20050445A NO 20050445 L NO20050445 L NO 20050445L
- Authority
- NO
- Norway
- Prior art keywords
- alovudine
- abacavir
- synergistic interaction
- treatment
- combined
- Prior art date
Links
- UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 title abstract 4
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 title abstract 4
- 229960004748 abacavir Drugs 0.000 title abstract 4
- 229950004424 alovudine Drugs 0.000 title abstract 4
- 230000009044 synergistic interaction Effects 0.000 title 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202022A SE0202022D0 (sv) | 2002-06-27 | 2002-06-27 | Synergistic interaction of abacavir and alovudine |
| EP02024744 | 2002-11-06 | ||
| PCT/SE2003/001100 WO2004002433A1 (en) | 2002-06-27 | 2003-06-24 | Synergistic interaction of abacavir and alovudine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20050445L true NO20050445L (no) | 2005-01-26 |
Family
ID=30001852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20050445A NO20050445L (no) | 2002-06-27 | 2005-01-26 | Synergistisk interaksjon mellom abacavir og alovudin |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060084627A1 (pl) |
| EP (1) | EP1536800B1 (pl) |
| JP (1) | JP2005533870A (pl) |
| KR (1) | KR20050013628A (pl) |
| CN (1) | CN1302779C (pl) |
| AT (1) | ATE314851T1 (pl) |
| AU (1) | AU2003239088B2 (pl) |
| BR (1) | BR0311141A (pl) |
| CA (1) | CA2481890A1 (pl) |
| DE (1) | DE60303131T2 (pl) |
| ES (1) | ES2254941T3 (pl) |
| HK (1) | HK1079981B (pl) |
| IL (1) | IL164921A0 (pl) |
| MX (1) | MXPA04012754A (pl) |
| NO (1) | NO20050445L (pl) |
| NZ (1) | NZ535817A (pl) |
| PL (1) | PL373758A1 (pl) |
| RU (1) | RU2320347C2 (pl) |
| WO (1) | WO2004002433A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1610797A1 (en) * | 2003-03-27 | 2006-01-04 | Boehringer Ingelheim International GmbH | Antiviral combination of nevirapine and a further antiretroviral compound |
| GB0608876D0 (en) | 2006-05-05 | 2006-06-14 | Medivir Ab | Combination therapy |
| EP3351249A1 (en) * | 2010-01-27 | 2018-07-25 | VIIV Healthcare Company | Antiviral therapy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5446029A (en) * | 1986-07-04 | 1995-08-29 | Medivir Ab | Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides |
| SE8602981D0 (sv) * | 1986-07-04 | 1986-07-04 | Astra Laekemedel Ab | Novel medicinal use |
| GB8719877D0 (en) * | 1987-08-22 | 1987-09-30 | Wellcome Found | Antiviral compounds |
| NZ229453A (en) * | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
| SE464168B (sv) * | 1989-07-19 | 1991-03-18 | Bo Fredrik Oeberg | Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt) |
| MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| US6395716B1 (en) * | 1998-08-10 | 2002-05-28 | Novirio Pharmaceuticals Limited | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
| GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| AU781281B2 (en) * | 1999-01-22 | 2005-05-12 | Emory University | HIV-1 mutations selected for by beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine |
| US6514979B1 (en) * | 1999-03-03 | 2003-02-04 | University Of Maryland Biotechnology Institute | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor |
| AU2001275166B2 (en) * | 2000-06-02 | 2005-07-28 | Smithkline Beecham Corporation | Methods of treating viral diseases with il-18 and il-18 combinations |
-
2003
- 2003-06-24 BR BR0311141-5A patent/BR0311141A/pt not_active IP Right Cessation
- 2003-06-24 JP JP2004548906A patent/JP2005533870A/ja active Pending
- 2003-06-24 WO PCT/SE2003/001100 patent/WO2004002433A1/en not_active Ceased
- 2003-06-24 PL PL03373758A patent/PL373758A1/pl not_active Application Discontinuation
- 2003-06-24 AU AU2003239088A patent/AU2003239088B2/en not_active Ceased
- 2003-06-24 CA CA002481890A patent/CA2481890A1/en not_active Abandoned
- 2003-06-24 CN CNB038151685A patent/CN1302779C/zh not_active Expired - Fee Related
- 2003-06-24 US US10/519,332 patent/US20060084627A1/en not_active Abandoned
- 2003-06-24 MX MXPA04012754A patent/MXPA04012754A/es active IP Right Grant
- 2003-06-24 DE DE60303131T patent/DE60303131T2/de not_active Expired - Fee Related
- 2003-06-24 HK HK06100011.9A patent/HK1079981B/zh not_active IP Right Cessation
- 2003-06-24 AT AT03733801T patent/ATE314851T1/de not_active IP Right Cessation
- 2003-06-24 EP EP03733801A patent/EP1536800B1/en not_active Expired - Lifetime
- 2003-06-24 ES ES03733801T patent/ES2254941T3/es not_active Expired - Lifetime
- 2003-06-24 KR KR10-2004-7021155A patent/KR20050013628A/ko not_active Ceased
- 2003-06-24 RU RU2005101874/15A patent/RU2320347C2/ru not_active IP Right Cessation
- 2003-06-24 NZ NZ535817A patent/NZ535817A/en not_active IP Right Cessation
-
2004
- 2004-10-28 IL IL16492104A patent/IL164921A0/xx unknown
-
2005
- 2005-01-26 NO NO20050445A patent/NO20050445L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE314851T1 (de) | 2006-02-15 |
| ES2254941T3 (es) | 2006-06-16 |
| KR20050013628A (ko) | 2005-02-04 |
| PL373758A1 (pl) | 2005-09-05 |
| WO2004002433A1 (en) | 2004-01-08 |
| CN1665509A (zh) | 2005-09-07 |
| HK1079981A1 (en) | 2006-04-21 |
| HK1079981B (zh) | 2007-10-12 |
| RU2005101874A (ru) | 2005-06-27 |
| DE60303131D1 (de) | 2006-03-30 |
| CN1302779C (zh) | 2007-03-07 |
| DE60303131T2 (de) | 2006-07-20 |
| AU2003239088B2 (en) | 2006-11-02 |
| WO2004002433A8 (en) | 2004-05-06 |
| RU2320347C2 (ru) | 2008-03-27 |
| IL164921A0 (en) | 2005-12-18 |
| EP1536800B1 (en) | 2006-01-04 |
| AU2003239088A1 (en) | 2004-01-19 |
| CA2481890A1 (en) | 2004-01-08 |
| JP2005533870A (ja) | 2005-11-10 |
| EP1536800A1 (en) | 2005-06-08 |
| BR0311141A (pt) | 2005-06-07 |
| US20060084627A1 (en) | 2006-04-20 |
| MXPA04012754A (es) | 2005-03-23 |
| NZ535817A (en) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035500A1 (es) | Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina. | |
| EE05074B1 (et) | Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid | |
| MXPA03007712A (es) | Sales farmaceuticas. | |
| AR032293A1 (es) | Estuche farmaceutico | |
| UY26372A1 (es) | "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen " | |
| CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
| DK1259240T3 (da) | Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme | |
| ATE291908T1 (de) | Ibuprofen-wirkstoffzubereitung | |
| GB0002336D0 (en) | Medicaments | |
| ZA200208761B (en) | Pharmaceutical form of administration for peptides, methods for its production and use. | |
| SI1404304T1 (sl) | Tableta, obsegajoča cetirizin in psevdoefedrin | |
| DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
| BG108452A (en) | Tablet comprising cetirizine and pseudoephedrine | |
| EE05241B1 (et) | Distamtsiini a-halogenoakrlolderivaadi kasutamine | |
| MXPA04001912A (es) | Aminobenzofenonas novedosas. | |
| HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| DE60303131D1 (de) | Synergistische wechselwirkung von abacavir und alovudin | |
| ATE261732T1 (de) | Pharmazeutische zusammensetzung, umfassend eukalyptus- und orangenöl | |
| EP1273301A3 (en) | Pharmaceutical preparations based on active ingredients susceptible to illict administration | |
| AU2003281468A1 (en) | P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient | |
| AU2002256775A1 (en) | Therapeutic method for inducing tolerance | |
| AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación | |
| AU2002225097A1 (en) | Novel therapeutic use of a thienylcyclohexylamine derivative | |
| DE50307169D1 (de) | ORALE VAKZINIERUNG MIT DEM TUMOR-ANTIGEN-MIMOTOP Gln-Met-Trp-Ala-Pro-Gln-Trp-Gly-Pro-Asp | |
| SE0000332D0 (sv) | New use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |